Astellas debuts Kiklin capsules, for hyperphosphatemia, in Japan

26 June 2012

Japanese drug major Astellas Pharma (TYO: 4503) yesterday launched Kiklin capsules 250mg (bixalomar) onto the Japanese market for the treatment of hyperphosphatemia in patients on dialysis with chronic kidney disease.

Under a strategic alliance established in February 2012 between Astellas and Sanwa Kagaku Kenkyusho for Japan’s pharmaceutical market in kidney disease, both companies will co-promote Kiklin capsules while Astellas will oversee distribution of the product. Astellas anticipates that peak sales of Kiklin may reach 7 billion yen (about $87 million) based on the NHI drug price in fiscal year 2016.

In April 2006, Astellas and Ilypsa, now a wholly-owned subsidiary of Amgen, entered into a license agreement that gives Astellas exclusive rights to develop and market Kiklin Capsules for the treatment of hyperphosphatemia in Japan.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK